Dimensional Fund Advisors LP Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Dimensional Fund Advisors LP increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 0.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,395,896 shares of the company's stock after buying an additional 28,104 shares during the period. Eli Lilly and Company comprises approximately 0.6% of Dimensional Fund Advisors LP's holdings, making the stock its 12th largest position. Dimensional Fund Advisors LP owned 0.36% of Eli Lilly and Company worth $1,979,508,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LLY. International Assets Investment Management LLC boosted its holdings in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company's stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the period. Sapient Capital LLC bought a new position in Eli Lilly and Company in the 4th quarter worth $682,139,000. J.P. Morgan Private Wealth Advisors LLC bought a new position in Eli Lilly and Company in the 3rd quarter worth $435,736,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company's stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company's stock valued at $1,778,362,000 after purchasing an additional 645,473 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 1.5 %

Shares of NYSE:LLY traded down $11.55 during trading on Friday, reaching $760.00. 2,082,289 shares of the company were exchanged, compared to its average volume of 2,926,412. The firm has a market capitalization of $722.31 billion, a PE ratio of 111.93, a P/E/G ratio of 1.53 and a beta of 0.37. The business's fifty day simple moving average is $761.48 and its 200-day simple moving average is $677.52. Eli Lilly and Company has a 12-month low of $419.80 and a 12-month high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period last year, the company posted $1.62 earnings per share. The company's quarterly revenue was up 26.0% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company's dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a report on Friday, February 16th. DZ Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating and set a $820.00 price objective for the company. in a report on Wednesday, February 21st. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 3rd. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a report on Thursday, April 11th. Finally, Bank of America upped their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.